Summit Therapeutics
Summit Therapeutics Inc is an American biopharmaceutical company developing novel oncology therapies. The company's lead candidate, ivonescimab, is a bispecific antibody combining anti-PD-1 and anti-VEGF mechanisms designed to improve outcomes in non-small cell lung cancer and other solid tumors. Main revenue drivers currently comprise development partnership milestones, licensing agreements, and capital markets financing as Phase III clinical trials advance. Summit Therapeutics targets medical oncologists, clinical research hospitals, biopharmaceutical partners, and lung cancer patients across North America, South America, and Europe. The company holds a prominent market position in bispecific antibody development for precision oncology. Headquartered in Miami, Florida, Summit Therapeutics Inc is listed on the Nasdaq Stock Market.
5 of the funds FundTelligence covers report a position in Summit Therapeutics.
- Legal name
- Summit Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
Funds holding Summit Therapeutics
- DNB Bioteknologi — DNB · 2.05 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.84 % (full portfolio disclosed, October 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 0.43 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)